105 related articles for article (PubMed ID: 2653488)
1. Detection of minimal residual disease in acute myelogenous leukemia by RNA-in situ hybridization.
Evinger-Hodges MJ; Spinolo JA; Spencer V; Nieto P; Dicke KA
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():13-5. PubMed ID: 2653488
[TBL] [Abstract][Full Text] [Related]
2. myc and sis expression in acute myelogenous leukemia.
Evinger-Hodges MJ; Bresser J; Brouwer R; Cox I; Spitzer G; Dicke K
Leukemia; 1988 Jan; 2(1):45-9. PubMed ID: 2448556
[TBL] [Abstract][Full Text] [Related]
3. Expression of the protooncogenes c-myc, c-fos, and c-fms in acute myelocytic leukemia at diagnosis and in remission.
Preisler HD; Kinniburgh AJ; Wei-Dong G; Khan S
Cancer Res; 1987 Feb; 47(3):874-80. PubMed ID: 2433029
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
5. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation.
Murohashi I; Endho K; Nishida S; Yoshida S; Jinnai I; Bessho M; Hirashima K
Exp Hematol; 1995 Aug; 23(9):970-7. PubMed ID: 7543418
[TBL] [Abstract][Full Text] [Related]
8. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.
Abbaszadegan MR; Futscher BW; Klimecki WT; List A; Dalton WS
Cancer Res; 1994 Sep; 54(17):4676-9. PubMed ID: 8062263
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the proto-oncogenes c-sis, c-fos, c-myc and c-myb in acute myeloid leukemias.
Strassburg CP; Neubauer V; Poliwoda H; Benter T
Neoplasma; 1992; 39(6):343-7. PubMed ID: 1491723
[TBL] [Abstract][Full Text] [Related]
11. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
12. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia.
Huh HJ; Huh JW; Yoo ES; Seong CM; Lee M; Hong KS; Chung WS
Am J Hematol; 2005 Aug; 79(4):267-73. PubMed ID: 16044449
[TBL] [Abstract][Full Text] [Related]
13. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Mahlknecht U; Schönbein C
Haematologica; 2008 Mar; 93(3):443-6. PubMed ID: 18268283
[TBL] [Abstract][Full Text] [Related]
15. Differing patterns of human protooncogene expression in peripheral blood and bone marrow acute leukemia cells.
Preisler HD; Sato H; Li YQ; Stein G; Stein J
Cancer Res; 1987 Jul; 47(14):3747-51. PubMed ID: 3474060
[TBL] [Abstract][Full Text] [Related]
16. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
17. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
18. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
20. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
